Skip to main content

Rizatriptan Benzoate

FDA recalls

2 rows

DateCompany and reasonClass
Jul 8, 2025Ascend Laboratories, LLC
CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
Class II · Ongoing
Oct 17, 2021Macleods Pharma USA, Inc
Out-of-specification test results obtained in Organic Impurities test during analysis of controlled samples.
Class III · Terminated

← Back to Rizatriptan Benzoate

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).